[1M16-18] Medical RI Manufacturing

[1M16] Development of Liquid Bi Target for Continuous Production of Therapeutic Radionuclide Astatine-211

(1)Liq. Bi target project overview

*Noriko S. Ishioka¹, Shigeki Watanabe¹, Hiroo Kondo³, Toshihide Takai², Tomohiro Furukawa² (1. QST, 2. JAEA, 3. QST(present affiliation:MHI))

Keywords:Bismuth, Liquid metal, Ion beams, Radionuclide production, Targeted radionuclide therapy

Alpha(α)-emitting radionuclide, astatine-211 (²¹¹At), has potential as a next-generation anti-cancer drug. The ²⁰⁹Bi(α,2n)²¹¹At reaction is required to produce large amount of ²¹¹At. However, bismuth (Bi) target is readily melted by an irradiation with high beam current due to its low melting point, which has limited the scale-up of ²¹¹At production. Purpose of this study is to formulate and verify an innovative concept for the large scale production of ²¹¹At using molten-Bi (liquid Bi target).